Dataciencia

Colección SciELO Chile

How Do I Assess Tremor Using Novel Technology?

Indexado

WoS	WOS:000496471500023
Scopus	SCOPUS_ID:85074669748

DOI

10.1002/MDC3.12818

Año

2019

Tipo

material editorial

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras

Abstract

Transducers are defined as any sensor that converts a physiological signal of tremor into an electrical signal. Evolving technologies have utilized transducers to develop devices for tremor measurement that are more convenient, accurate, and capable of continuous recording. Transducer-based methods provide valuable diagnostic tools for the clinician that can distinguish between different tremor syndromes and differentiate tremor from other hyperkinetic movement disorders. Transducers are also used to objectively quantify and track tremor symptom severity over time and assess clinical response to intervention (e.g., pharmaceutical treatments or DBS). This video highlights the utility of transducer-based methods in characterizing and quantifying tremor and reviews the available technologies for measuring tremor. We provide case examples that demonstrate how different technology-based measures for tremor direct the approach to diagnosis and management of symptoms.

Revista

Revista	ISSN
Movement Disorders Clinical Practice	2330-1619

Métricas Externas

PlumX	Altmetric	Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Plumx: https://plumanalytics.com/learn/about-metrics/
Altmetric: https://www.altmetric.com/about-altmetrics/what-are-altmetrics/
Dimensions: https://www.dimensions.ai/why-dimensions/

Disciplinas de Investigación

WOS
Clinical Neurology

Scopus
Neurology (Clinical)
Neurology

SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional

Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.

Autores - Afiliación

Ord.	Autor	Género	Institución - País
1	Longardner, Katherine	Mujer	Univ Calif San Diego - Estados Unidos Department of Neurosciences - Estados Unidos
2	Undurraga, Felipe Vial	Hombre	NINDS - Estados Unidos Universidad del Desarrollo - Chile National Institute of Neurological Disorders and Stroke - Estados Unidos Clínica Alemana - Chile National Institute of Neurological Disorders and Stroke (NINDS) - Estados Unidos
3	Nahab, Fatta B.	-	Univ Calif San Diego - Estados Unidos Department of Neurosciences - Estados Unidos
4	Hallett, Mark	Hombre	NINDS - Estados Unidos National Institute of Neurological Disorders and Stroke - Estados Unidos National Institute of Neurological Disorders and Stroke (NINDS) - Estados Unidos
5	Haubenberger, Dietrich	Hombre	NINDS - Estados Unidos National Institute of Neurological Disorders and Stroke - Estados Unidos National Institute of Neurological Disorders and Stroke (NINDS) - Estados Unidos

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento

Fuente
National Institutes of Health
University of California, San Diego
National Institute of Neurological Disorders and Stroke
NINDS Intramural Research Program
NIH Intramural Program
Cala Health Inc.
UC San Diego Parkinson and other Movement Disorders Center

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos

Agradecimiento
Dr. Katherine Longardner received honoraria from the Lundbeck Neurogenic Orthostatic Hypotension Fellows Advisory Board (Aug. 2018, Aspen, CO). Dr. Felipe Vial Undurraga received salary support through a research project funded by Cala Health Inc. Dr. Fatta Nahab received honoraria from Auspex Pharmaceuticals. Dr. Hallett may accrue revenue on US Patent #6,780,413 B2 (Issued: August 24, 2004): Immunotoxin (MAB‐Ricin) for the treatment of focal movement disorders, and US Patent #7,407,478 (Issued: August 5, 2008): Coil for Magnetic Stimulation and methods for using the same (H‐coil); in relation to the latter, he has received license fee payments from the NIH (from Brainsway) for licensing of this patent. He is on the medical advisory boards of CALA Health, Brainsway, and Cadent. He is on the editorial boards of approximately 15 journals and receives royalties and/or honoraria from publishing from Cambridge University Press, Oxford University Press, Springer, and Elsevier. Dr. Hallett's research at the NIH is largely supported by the NIH Intramural Program. Supplemental research funds have been granted by Allergan for studies of methods to inject botulinum toxins, Medtronic, Inc. for a study of DBS for dystonia, and CALA Health for studies of a device to suppress tremor. Dr. Dietrich Haubenberger is Special Volunteer at the National Institutes of Neurological Disorders and Stroke, under which capacity the manuscript for this article was developed. Since January 2019, Dr. Haubenberger is an employee of Neurocrine Biosciences, Inc.
This study was supported by the NINDS Intramural Research Program. Dr. Nahab reports a consultancy with Global Kinetics PTY.
This study was supported by the NINDS Intramural Research Program. Dr. Nahab reports a consultancy with Global Kinetics PTY.
We thank Scott McAvoy, Digital Media Lab Manager at UC San Diego, for digital media production. We thank Dr. Irene Litvan, Director of the UC San Diego Parkinson and other Movement Disorders Center.
Dr. Katherine Longardner received honoraria from the Lundbeck Neurogenic Orthostatic Hypotension Fellows Advisory Board (Aug. 2018, Aspen, CO). Dr. Felipe Vial Undurraga received salary support through a research project funded by Cala Health Inc. Dr. Fatta Nahab received honoraria from Auspex Pharmaceuticals. Dr. Hallett may accrue revenue on US Patent #6,780,413 B2 (Issued: August 24, 2004): Immunotoxin (MAB‐Ricin) for the treatment of focal movement disorders, and US Patent #7,407,478 (Issued: August 5, 2008): Coil for Magnetic Stimulation and methods for using the same (H‐coil); in relation to the latter, he has received license fee payments from the NIH (from Brainsway) for licensing of this patent. He is on the medical advisory boards of CALA Health, Brainsway, and Cadent. He is on the editorial boards of approximately 15 journals and receives royalties and/or honoraria from publishing from Cambridge University Press, Oxford University Press, Springer, and Elsevier. Dr. Hallett's research at the NIH is largely supported by the NIH Intramural Program. Supplemental research funds have been granted by Allergan for studies of methods to inject botulinum toxins, Medtronic, Inc. for a study of DBS for dystonia, and CALA Health for studies of a device to suppress tremor. Dr. Dietrich Haubenberger is Special Volunteer at the National Institutes of Neurological Disorders and Stroke, under which capacity the manuscript for this article was developed. Since January 2019, Dr. Haubenberger is an employee of Neurocrine Biosciences, Inc.